Formulation and Evaluation of Taste-Masked Orally Disintegrating Tablets of Nicergoline based on β-cyclodextrin Inclusion Complexation

Complexation of nicergoline with β-cyclodextrin (β-CD) into an inclusion complex has been used successfully to improve the drug’s solubility, dissolution rate and hence per oral absorption. In addition, masking of the bitter taste was also achieved. The preparation of inclusion complexes was performed using two different techniques, namely; physical mixing and kneading. The apparent stability constant (Kc) of the complex was calculated from the phase solubility analysis. Compatibility of nicergoline and β-CD complex with disintegrants and superdisintegrants were evaluated using powder x-ray diffractometry (PXRD), differential scanning calorimetry (DSC), and fourier transform infrared spectroscopy (FTIR). The morphology of complex particles was studied using scanning electron microscopy. Pharmaceutical characterization confirmed that all additives were compatible with the drug and no signs of physical or chemical interaction were detected. Orodispersible tablets (ODTs) of nicergoline complexed with β-CD and containing 7-9 % camphor had rapid disintegration time (7-12 seconds) and fast drug release profiles (90-100 % in 10 minutes). Therefore, nicergoline ODTs are considered a valuable choice dosage form with improved per oral absorption and taste acceptability

Formulation and Evaluation of Taste-Masked Orally Disintegrating Tablets of Nicergoline based on β-cyclodextrin Inclusion Complexation

Complexation of nicergoline with β-cyclodextrin (β-CD) into an inclusion complex has been used successfully to improve the drug’s solubility, dissolution rate and hence per oral absorption. In addition, masking of the bitter taste was also achieved. The preparation of inclusion complexes was performed using two different techniques, namely; physical mixing and kneading. The apparent stability constant (Kc) of the complex was calculated from the phase solubility analysis. Compatibility of nicergoline and β-CD complex with disintegrants and superdisintegrants were evaluated using powder x-ray diffractometry (PXRD), differential scanning calorimetry (DSC), and fourier transform infrared spectroscopy (FTIR). The morphology of complex particles was studied using scanning electron microscopy. Pharmaceutical characterization confirmed that all additives were compatible with the drug and no signs of physical or chemical interaction were detected. Orodispersible tablets (ODTs) of nicergoline complexed with β-CD and containing 7-9 % camphor had rapid disintegration time (7-12 seconds) and fast drug release profiles (90-100 % in 10 minutes). Therefore, nicergoline ODTs are considered a valuable choice dosage form with improved per oral absorption and taste acceptability

Enhanced Antibacterial Activity of Clindamycin Using Molecularly Imprinted Polymer Nanoparticles Loaded with Polyurethane Nanofibrous Scaffolds for the Treatment of Acne Vulgaris

Acne vulgaris, a prevalent skin condition, arises from an imbalance in skin flora, fostering bacterial overgrowth. Addressing this issue, clindamycin molecularly imprinted polymeric nanoparticles (Clin-MIP) loaded onto polyurethane nanofiber scaffolds were developed for acne treatment. Clin-MIP was synthesized via precipitation polymerization using methacrylic acid (MAA), ethylene glycol dimethacrylate (EGDMA), and azoisobutyronitrile (AIBN) as functional monomers, crosslinkers, and free-radical initiators, respectively. MIP characterization utilized Fourier-transform infrared spectroscopy (FTIR) and transmission electron microscopy (TEM) before being incorporated into polyurethane nanofibers through electrospinning. Further analysis involved FTIR, scanning electron microscopy (SEM), in vitro release studies, and an ex vivo study. Clin-MIP showed strong antibacterial activity against S. aureus, with inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values of 0.39 and 6.25 μg/mL, respectively. It significantly dropped the bacterial count from 1 × 108 to 39 × 101 CFU/mL in vivo and has bactericidal activity within 180 min of incubation in vitro. The pharmacodynamic and histopathology studies revealed a significant decrease in infected animal skin inflammation, epidermal hypertrophy, and congestion upon treatment with Clin-MIP polyurethane nanofiber and reduced pro-inflammatory cytokines (NLRP3, TNF-α, IL-1β, and IL-6) conducive to acne healing. Consequently, the recently created Clin-MIP polyurethane nanofibrous scaffold. This innovative approach offers insight into creating materials with several uses for treating infectious wounds caused by acne